A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

NCT00823979 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
105
Enrollment
INDUSTRY
Sponsor class

Stopped See termination reason in detailed description.

Conditions

Interventions

Sponsor

Pfizer